Using pomalidomide to treat bleeding in patients with hereditary hemorrhagic telangiectasia.
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
This study is looking at how well the medication pomalidomide can help people with hereditary hemorrhagic telangiectasia (HHT) manage their nosebleeds and other bleeding issues, while also keeping an eye on any side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10581634 on NIH RePORTER |
What this research studies
This research investigates the use of pomalidomide, a medication that may help reduce bleeding in patients with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that causes abnormal blood vessel formations. The study aims to assess the effectiveness of pomalidomide in managing symptoms such as nosebleeds and gastrointestinal bleeding, which are common in HHT patients. Participants will be monitored for changes in bleeding frequency and severity, as well as any potential side effects from the treatment. The research builds on previous findings that suggest thalidomide could be beneficial, but focuses on pomalidomide due to its lower toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hereditary hemorrhagic telangiectasia who experience frequent or severe bleeding episodes.
Not a fit: Patients who do not have hereditary hemorrhagic telangiectasia or those with mild symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from severe bleeding due to hereditary hemorrhagic telangiectasia.
How similar studies have performed: Previous studies have shown some promise with thalidomide in treating HHT, but this approach using pomalidomide is relatively novel.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Mccrae, Keith R. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Mccrae, Keith R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.